111 filings
Page 3 of 6
8-K
5wn5k4do2
1 Jul 21
Highlights the broader potential of Orchard’s ex vivo HSC gene therapy platform approach in new and larger indications
5:02pm
8-K
yvb2pn3ajzou yglu7b0
29 Jun 21
Orchard Therapeutics Announces Regulatory and Clinical Updates for Lead Gene Therapy Programs
7:05am
8-K
ol7jx6j6x
22 Jun 21
Submission of Matters to a Vote of Security Holders
7:05am
8-K
vqpwtx8oxhk7o2j
4 Jun 21
Entry into a Material Definitive Agreement
7:05am
8-K
zewy8t8hp qbndb
28 May 21
Other Events
4:36pm
8-K
pecq4qiyj2800p
13 May 21
Orchard Therapeutics Reports First Quarter 2021 Financial Results and Provides Recent Business Updates
7:05am
8-K
qgrh fhech
11 May 21
Orchard Therapeutics Announces New England Journal of Medicine Publication of HSC Gene Therapy Data for ADA-SCID
6:05am
8-K
u67vzyrpiit48rp6po0y
14 Apr 21
Termination of a Material Definitive Agreement
4:03pm
8-K
x4ma2z8xvxhv qq
2 Mar 21
Orchard Therapeutics Reports 2020 Financial Results and Reviews Recent Accomplishments
7:05am
8-K
uph24hq
9 Feb 21
Orchard Therapeutics Announces $150 Million Strategic Financing
7:10am
8-K
fpaipo5i o9khy3d
29 Jan 21
Orchard Therapeutics Appoints Braden Parker as Chief Commercial Officer
7:03am
8-K
s87w2lzkt qhq5
19 Jan 21
Orchard Therapeutics Secures Partnerships to Broaden Access to LibmeldyTM for Eligible Patients in Middle East & Turkey
7:03am
8-K
olj1d2 9a59
14 Jan 21
Interactions with FDA anticipated by mid-2021 to determine the BLA filing strategy for OTL-200
7:03am
8-K
v65dxdw5n
11 Jan 21
Results of Operations and Financial Condition
7:05am
8-K
6y58c56j d0
21 Dec 20
First gene therapy to receive full EU marketing authorization for eligible MLD patients
7:03am
8-K
235xy14xwofmsbu1
8 Dec 20
Other Events
7:03am
8-K
feda7hmvq2xnjv7fm8p
19 Nov 20
Other Events
7:03am
8-K
ijjc09cd
12 Nov 20
NOD2 mutation revealed as Crohn’s disease (CD) genetic target, associated with 7-10% of all CD cases in the U.S. and Europe
4:18pm
8-K
4b5ymbla
5 Nov 20
Other Events
7:03am
8-K
tggjwr55y36z3pv83
3 Nov 20
Orchard Therapeutics Reviews Recent Portfolio Progress and Reports Third Quarter 2020 Financial Results
7:03am